Release
📈 Stocks
Riboscience to Present Phase 1b Data for ENPP1 Inhibitor RBS2418 at ESMO 2026
(1 day ago)
Riboscience prepares to showcase Phase 1b clinical data for its lead ENPP1 inhibitor, RBS2418, at the ESMO 2026 medical congress, marking a…